TOTAL: $22.5M
Year to Date: $515.37M

Company
(Symbol)#*

Partner
(Country)

Amt.
(M)

Triggering
Event

Details (Date)


Can-Fite
BioPharma Ltd.
(Israel; TEL:CFBI)

Seikagaku Corp. (Japan)

$0.5

Milestone payment

Triggered by enrollment of more than half the patients in a Phase IIb trial of CF101 in rheumatoid arthritis (10/23)

Curis Inc.
(CRIS)

Genentech Inc. (NYSE:DNA)

$3

Milestone payment

Triggered by Genentech's filing of an IND to initiate Phase I trials of a small- molecule Hedgehog antagonist for treating cancer (10/5)

Immunogen
Inc.
(IMGN)

Sanofi-Aventis SA (France)

$2

Milestone payment

Triggered by Sanofi's initiation of clinical testing of AVE1642, an antibody that binds to the insulin-like growth factor 1 receptor (10/4)

Indevus
Pharmaceuticals
Inc.
(IDEV)

Esprit Pharma Inc.

$10

Milestone payment

Triggered by submission of a new drug appli- cation with the FDA seeking approval of Sanctura for treating overactive bladder (10/18)

Memory
Pharmaceuticals
Corp.
(MEMY)

F. Hoffmann- La Roche Ltd. (Switzerland)

$2

Milestone payment

Triggered by Roche's decision to maintain its option to license MEM 3454, the lead compound from their deal on nicotinic alpha-7 receptor agonists for treating neurological disorders (10/31)

Progenics
Pharmaceuticals
Inc.
(PGNX)

Wyeth Pharmaceuticals

$5

Milestone payment

Triggered by Progenics' start of a Phase III trial of intravenous methylnaltrexone for treating postoperative ileus (10/25)


Notes:

# Unless otherwise indicated, shares are traded on the Nasdaq exchange.

TEL = Tel Aviv Stock Exchange.

No Comments